New blood test aims to catch liver cancer recurrence early

NCT ID NCT04856046

Ongoing Diagnosis Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new blood test that looks for DNA changes to detect if liver cancer has come back or spread after surgery. Researchers at Mayo Clinic are enrolling 36 patients with early-stage liver cancer who are scheduled for surgery. The goal is to see if this test can help doctors monitor patients better and make more informed treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Blood test (multi-target hepatocellular carcinoma blood test, mt-HBT)
What this could lead to: If successful, this blood test could help doctors detect liver cancer recurrence earlier and personalize treatment, potentially improving outcomes.
What could go wrong: This is a small, early-phase study with only 36 participants. The test may not prove accurate enough for routine use, and results may not apply to all liver cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESECTABLE HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.